Recurrent Glioblastoma Treated with Recombinant Poliovirus

A replication-defective poliovirus was injected directly into recurrent glioblastoma tumors, and dexamethasone and bevacizumab were used to control edema. A total of 20% of the treated patients have survived beyond 3 years.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 379; no. 2; pp. 150 - 161
Main Authors Desjardins, Annick, Gromeier, Matthias, Herndon, James E, Beaubier, Nike, Bolognesi, Dani P, Friedman, Allan H, Friedman, Henry S, McSherry, Frances, Muscat, Andrea M, Nair, Smita, Peters, Katherine B, Randazzo, Dina, Sampson, John H, Vlahovic, Gordana, Harrison, William T, McLendon, Roger E, Ashley, David, Bigner, Darell D
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 12.07.2018
Subjects
Adult
Aged
Antigens
Brain cancer
Brain research
Brain tumors
Cell culture
Chimera
Clinical trials
Convection
Cytotoxicity
FDA approval
Female
Glioblastoma
Glioblastoma - mortality
Glioblastoma - therapy
Glioma
Glucocorticoids
Hemorrhage
Humans
Immunotherapy
Infections
Infusions, Intralesional
Male
Middle Aged
Neoplasm Recurrence, Local - therapy
Nervous system
Neurovirulence
Oncology
Oncolytic Virotherapy
Poliovirus
Population studies
Rhinovirus
Solid tumors
Survival Rate
Tissue culture
Toxicity
Young Adult
Online AccessGet full text

Cover

More Information
Summary:A replication-defective poliovirus was injected directly into recurrent glioblastoma tumors, and dexamethasone and bevacizumab were used to control edema. A total of 20% of the treated patients have survived beyond 3 years.
Bibliography:Drs. Desjardins and Gromeier and Drs. Ashley and Bigner contributed equally to this article.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1716435